ライフサイエンスコーパス: papillomavirus

1 inst human papillomavirus and low-risk human papillomavirus.

2 the E6 and E7 oncoproteins of two oncogenic papillomaviruses.

3 have been demonstrated for multiple types of papillomaviruses.

4 lving a conserved tyrosine (Y) in the bovine papillomavirus 1 (BPV-1) E2 protein at amino acid 102.

5 Here we have discovered that the bovine papillomavirus 1 (BPV-1) transcription and replication r

6 Recent biochemical studies on bovine papillomavirus 1 (BPV1) E1 showed that the AR and C-tail

7 Mus musculus papillomavirus 1 (MmuPV1/MusPV1) induces persistent papi

8 assessed the importance of the CTD of human papillomavirus 11 (HPV11) E1 in vivo, using a cell-based

9 Human papillomavirus 11 (HPV11) is an etiological agent of ano

10 racycline-inducible vector system, and human papillomavirus 16 (HPV 16) E6 and E7 gene-immortalized n

11 Both human papillomavirus 16 (HPV16) and bovine papillomavirus (BPV

12 The association between oral human papillomavirus 16 (HPV16) DNA load and infection clearan

13 leavage of capsid-associated L2 during human papillomavirus 16 (HPV16) infection remains poorly chara

14 Human papillomavirus 16 (HPV16) is causative in many human can

15 Human papillomavirus 16 (HPV16) is the most prevalent oncogeni

16 t, dramatically decreased infection of human papillomavirus 16 (HPV16) pseudovirus (PsV).

17 ovel interaction between Rint1 and the human papillomavirus 16 (HPV16) transcription and replication

18 luding bovine papillomavirus (BPV) and human papillomavirus 16 (HPV16), associate with the cellular D

19 A human papillomavirus 16 (HPV16)-targeted version of the DNA va

20 1 month after the last dose of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/18) va

21 Human papillomavirus 18 (HPV18) is the second most common onco

22 ated with the BPV-1 E2 protein, as did human papillomavirus 31 (HPV-31) E2, which also colocalized wi

23 ralia, high uptake of the quadrivalent human papillomavirus (4vHPV) vaccine has led to reductions in

24 Human papillomavirus 58 (HPV58) is found in 10 to 18% of cervi

25 sphorylated peptide motif derived from human papillomavirus 8 (HPV-8), the E2 hinge region including

26 ars showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52

27 arcinoma (SCC) is associated with both human papillomavirus and HIV infection.

28 r male circumcision protecting against human papillomavirus and low-risk human papillomavirus.

29 in RTOG 0129 (2002 to 2005) with known human papillomavirus and smoking status.

30 t DNA viruses (anelloviruses, herpesviruses, papillomaviruses and polyomaviruses) over time were obse

31 e sequences of over 300 genetically distinct papillomaviruses and provides evidence for a role of gen

32 , several human tumor viruses, including the papillomaviruses and the gammaherpesviruses, maintain th

33 Both the papillomaviruses and the polyomaviruses have served as t

34 l insight into the complex interplay between papillomaviruses and their hosts.

35 The following search terms were used: "human papillomavirus" and "cutaneous squamous cell carcinoma o

36 h known p16 tumor status (surrogate of human papillomavirus) and cigarette smoking history (pack-year

37 Papillomaviruses are small, double-stranded DNA viruses

38 Human papillomaviruses are the causative agents of cervical, a

39 de a tractable system for further dissecting papillomavirus assembly.

40 ith the recently described epidemic of human papillomavirus-associated head and neck squamous cell ca

41 ll responses in complete regression of human papillomavirus-associated metastatic cervical cancer aft

42 ing the association between beta-genus human papillomavirus (beta-HPV) and cutaneous squamous cell ca

43 ted the association between beta genus human papillomaviruses (betaPV) and keratinocyte carcinoma in

44 verse papillomavirus types, including bovine papillomavirus (BPV) and human papillomavirus 16 (HPV16)

45 h human papillomavirus 16 (HPV16) and bovine papillomavirus (BPV1) E7 proteins are capable of partial

46 The virus coat (capsid) of the human papillomavirus contains major (L1) and minor (L2) capsid

47 be a valuable model for the study of mucosal papillomavirus disease, progression, and host immune con

48 erichia coli, influenza virus, cancer, human papillomavirus, dopamine, glutamic acid, IgG, IgE, uric

49 americ DNA helicases from superfamily 3, the papillomavirus E1 helicase contains a unique C-terminal

50 attached to the AAA+ helicase domain in the papillomavirus E1 protein allows the formation of differ

51 scribe a switching mechanism that allows the papillomavirus E1 protein to form these two different ki

52 The papillomavirus E1 protein, as many other helicases, has

53 ChlR1 is required for loading of the bovine papillomavirus E2 protein onto chromatin during DNA synt

54 We tested the papillomavirus E6 and E7 oncoproteins in three functiona

55 In a third assay, papillomavirus E7 has the same effect as the murine poly

56 ral oncoproteins, such as adenovirus E1A and papillomavirus E7, inactivate Rb.

57 cation and raised the possibility that, like papillomaviruses, EBV has evolved to take advantage of e

58 Human papillomaviruses enter host cells via a clathrin-indepen

59 The Papillomavirus Episteme (PaVE) is a database of curated

60 st a novel size discrimination mechanism for papillomavirus genome packaging in which particles under

61 The papillomavirus genomes within PaVE have been further ann

62 of gene loss during the evolution of certain papillomavirus genomes.

63 rus Episteme (PaVE) is a database of curated papillomavirus genomic sequences, accompanied by web-bas

64 Oral human papillomavirus genotype 16 (HPV16) infection causes orop

65 Human papillomavirus genotype-specific concordance is more com

66 for the p16 protein, an indicator that human papillomavirus had a role in the causation of the cancer

67 Mouse papillomavirus has shown broad tissue tropism in nude mi

68 atherosclerosis, cancer), viral (e.g., human papillomavirus, herpes virus) and bacterial (e.g., Helic

69 f all HIV-infected women regardless of human papillomavirus history or sexual practices.

70 ess of the tremendous global impact of human papillomavirus (HPV) -caused cancers, refocus the discus

71 red regimens including 2 doses (2D) of human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine in gi

72 the natural history of high-risk anal human papillomavirus (HPV) among a multinational group of men

73 retroviral therapy (ART) and high-risk human papillomavirus (HPV) and cervical lesions in women livin

74 en mixed on whether naturally acquired human papillomavirus (HPV) antibodies may protect against subs

75 Head and neck cancers positive for human papillomavirus (HPV) are exquisitely radiosensitive.

76 Specific types of human papillomavirus (HPV) are strongly associated with the de

77 High-risk strains of human papillomavirus (HPV) are the causative agents of cervica

78 Laboratories now can choose from >100 human papillomavirus (HPV) assays for cervical screening.

79 The human papillomavirus (HPV) capsid is composed of the major cap

80 During the entry process, the human papillomavirus (HPV) capsid is trafficked to the trans-G

81 The human papillomavirus (HPV) capsid protein L2 is essential for

82 the endosome triggers uncoating of the human papillomavirus (HPV) capsid, whereupon host cyclophilins

83 Importance: Human papillomavirus (HPV) causes an increasing proportion of

84 Human papillomavirus (HPV) causes an increasing proportion of

85 Human papillomavirus (HPV) causes the majority of oropharyngea

86 revalence and risk factors for genital human papillomavirus (HPV) detection among men who deny ever e

87 al swabs for cytologic examination and human papillomavirus (HPV) detection and genotyping.

88 the temporal relationship between oral human papillomavirus (HPV) detection and risk of head and neck

89 Mycobacterium tuberculosis (MTB), and human papillomavirus (HPV) DNA based on a colorimetric paper-b

90 Methylation of the human papillomavirus (HPV) DNA has been proposed as a novel bi

91 Detection of human papillomavirus (HPV) DNA in genital samples may not alwa

92 re amongst the least understood of the Human Papillomavirus (HPV) encoded gene products.

93 Here we describe human papillomavirus (HPV) genomes that express marker protein

94 led to reductions in the prevalence of human papillomavirus (HPV) genotypes 6, 11, 16, and 18 in wome

95 The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) studies

96 Human papillomavirus (HPV) high-risk genotypes such as HPV-16

97 Australia instituted funded female human papillomavirus (HPV) immunization in 2007, followed by a

98 resentative prevalence data on genital human papillomavirus (HPV) in males in the United States, usin

99 Cutaneous beta human papillomavirus (HPV) infection across cutaneous and muco

100 Limited data are available on human papillomavirus (HPV) infection among human immunodeficie

101 (VM) may influence risk of persistent Human Papillomavirus (HPV) infection and cervical carcinogenes

102 lyze the associations between cervical human papillomavirus (HPV) infection and human immunodeficienc

103 t the type-specific prevalence of anal human papillomavirus (HPV) infection and risk factors for anal

104 Human papillomavirus (HPV) infection distinctly alters methyla

105 risk of sequential acquisition of anal human papillomavirus (HPV) infection following a type-specific

106 Human Papillomavirus (HPV) infection has been recognized as th

107 r, its association with cervicovaginal human papillomavirus (HPV) infection has not been studied.

108 n between vaginal douching and genital human papillomavirus (HPV) infection have found contrary resul

109 ed to explain the excess in detectable human papillomavirus (HPV) infection in Latin America, via a g

110 Human Papillomavirus (HPV) infection involves multiple steps,

111 Although the risk of human papillomavirus (HPV) infection is greatest in young wome

112 The epidemiology of penile human papillomavirus (HPV) infection is not well understood.

113 Human papillomavirus (HPV) infection, a primary cause of genit

114 igated bereavement in association with human papillomavirus (HPV) infection, both HPV16 and other HPV

115 carcinomas (OPSCCs) is attributable to human papillomavirus (HPV) infection.

116 n associated with an increased risk of human papillomavirus (HPV) infection.

117 ted with tobacco or alcohol use and/or human papillomavirus (HPV) infection.

118 ex with men (MSM) are at high risk for human papillomavirus (HPV) infection; vaccination is recommend

119 Although new human papillomavirus (HPV) infections can occur at all ages, t

120 The clustering of human papillomavirus (HPV) infections in some individuals is o

121 ned the concordance of penile and oral human papillomavirus (HPV) infections in the United States.

122 Prevalence of human papillomavirus (HPV) infections was assessed among 1033

123 We conducted a critical review of human papillomavirus (HPV) integration into the host genome in

124 Human papillomavirus (HPV) is a common sexually transmitted in

125 Human papillomavirus (HPV) is a recently identified causative

126 nity in preventing newly acquired oral human papillomavirus (HPV) is not well understood.

127 e presence of neutralizing epitopes in human papillomavirus (HPV) L1 virus-like particles (VLPs) is t

128 The human papillomavirus (HPV) life cycle is tightly linked to dif

129 The human papillomavirus (HPV) life cycle is tightly linked to dif

130 Population- wide vaccination against human papillomavirus (HPV) linked to cervical screening, at le

131 The human papillomavirus (HPV) major structural protein L1 compose

132 rally induced serum antibodies against human papillomavirus (HPV) may affect risks of subsequent inci

133 y those in immunocompromised patients, human papillomavirus (HPV) may be an important factor.

134 ecent birth cohorts vaccinated against human papillomavirus (HPV) may be protected against up to 4 ge

135 attributed to an increasing impact of human papillomavirus (HPV) on disease etiology.

136 ased expression of the major high-risk human-papillomavirus (HPV) oncogenes E6 and E7 in basal cervic

137 Recently, the human papillomavirus (HPV) oncoprotein E6 has been identified

138 The human papillomavirus (HPV) plays a central role in cervical ca

139 The E7 oncoprotein of the high-risk human papillomavirus (HPV) plays a major role in HPV-induced c

140 We assessed human papillomavirus (HPV) prevalence among HPV-16/18-vaccinat

141 From evaluations in human papillomavirus (HPV) protection models in rabbits and mi

142 The human papillomavirus (HPV) replication cycle is tightly linked

143 al cancer in England, UK, will change: human papillomavirus (HPV) screening will be the primary test

144 mportance: Pathology-based measures of human papillomavirus (HPV) status are routinely obtained in th

145 Pathology-based measures of human papillomavirus (HPV) status are routinely obtained in th

146 al cases with information available on human papillomavirus (HPV) status indicated that this associat

147 death ligand 1 (PD-L1) expression and human papillomavirus (HPV) status.

148 In 2000, the Hybrid Capture 2 human papillomavirus (HPV) test was approved by the U.S. Food

149 Using primary human papillomavirus (HPV) testing for cervical screening incr

150 Human papillomavirus (HPV) testing is used in primary cervical

151 cimens were collected for cytology and human papillomavirus (HPV) testing.

152 pared it with post-treatment high-risk human papillomavirus (HPV) testing.

153 Inexpensive and easy-to-perform human papillomavirus (HPV) tests are needed for primary cervic

154 e used a transmission dynamic model of human papillomavirus (HPV) to investigate the effect of ethnic

155 uence on biopsy and treatment rates of human papillomavirus (HPV) triage of cytology showing atypical

156 oscopic impression, HSIL cytology, and human papillomavirus (HPV) type 16 positivity.

157 tland launched routine vaccination for human papillomavirus (HPV) types 16 and 18, targeted at 12-13-

158 the relative carcinogenic potential of human papillomavirus (HPV) types among women infected with hum

159 We designed a universal human papillomavirus (HPV) typing assay based on target enrich

160 Incoming human papillomavirus (HPV) utilize vesicular transport to traf

161 Human papillomavirus (HPV) vaccination is still not reaching m

162 tudies have been widely used to inform human papillomavirus (HPV) vaccination policy decisions; howev

163 Human papillomavirus (HPV) vaccination programmes were first i

164 Prophylactic human papillomavirus (HPV) vaccination programs constitute maj

165 Reducing the number of doses in the human papillomavirus (HPV) vaccination regimen from 3 to 2 cou

166 Human papillomavirus (HPV) vaccination targeting females aged

167 Expanding routine human papillomavirus (HPV) vaccination to adults could be an e

168 ess of providing 3-doses of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females aged 13-

169 Uptake of human papillomavirus (HPV) vaccine among girls in the Dutch im

170 of antibody response following reduced human papillomavirus (HPV) vaccine doses has not been determin

171 en in the United States completing the human papillomavirus (HPV) vaccine doubled.

172 Human papillomavirus (HPV) vaccine effectiveness and herd prot

173 which targets a vaccine antigen in the human papillomavirus (HPV) vaccine Gardasil.

174 Uptake of human papillomavirus (HPV) vaccine in the United States is slo

175 In the United States, human papillomavirus (HPV) vaccine is recommended for 11- or 1

176 The quadrivalent human papillomavirus (HPV) vaccine is recommended for all girl

177 Decreasing human papillomavirus (HPV) vaccine prices makes scaling up of

178 The quadrivalent human papillomavirus (HPV) vaccine was licensed for use in 9-

179 Human papillomavirus (HPV) vaccine was recommended in 2006 for

180 A 9-valent human papillomavirus (HPV) vaccine, licensed in 2014, prevents

181 rtial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and H

182 ination with the prophylactic bivalent human papillomavirus (HPV) vaccine.

183 Human papillomavirus (HPV) vaccines are ideally administered b

184 The human papillomavirus (HPV) vaccines consist of major capsid pr

185 t generation bivalent and quadrivalent human papillomavirus (HPV) vaccines have been introduced in mo

186 Effectiveness of human papillomavirus (HPV) vaccines in the context of both gui

187 A substantial effect of human papillomavirus (HPV) vaccines on reducing HPV-related ce

188 The association between partner human papillomavirus (HPV) viral load and incident HPV detecti

189 Circumcision and lower human papillomavirus (HPV) viral loads in men are possibly ass

190 The high prevalence of human papillomavirus (HPV), the most common sexually transmitt

191 ol group, GUWE treated DCs pulsed with human papillomavirus (HPV)-16 E6/E7 peptides significantly inh

192 stic transformation of human cells, so human papillomavirus (HPV)-associated cancers will also rely u

193 the proteasomal degradation of p53 in human papillomavirus (HPV)-associated cancers.

194 Trends in human papillomavirus (HPV)-associated cervical lesions can pro

195 men (MSM) bear a substantial burden of human papillomavirus (HPV)-associated disease, prospective stu

196 Purpose Human papillomavirus (HPV)-associated oropharyngeal squamous c

197 ver, the role of gammadelta T cells in human papillomavirus (HPV)-associated uterine cervical SCC, th

198 and in a variety of cancers including human papillomavirus (HPV)-caused cervical cancer.

199 Importance: Human papillomavirus (HPV)-induced anogenital lesions are very

200 ned in CIN3, consistent with high-risk human papillomavirus (HPV)-induced tumor suppressor inactivati

201 vels were significantly upregulated in human papillomavirus (HPV)-infected cell lines and tissues.

202 Human papillomavirus (HPV)-negative head and neck squamous cel

203 Human papillomavirus (HPV)-negative oropharyngeal squamous cel

204 Patients with human papillomavirus (HPV)-positive head and neck squamous cel

205 The burden of human papillomavirus (HPV)-positive oropharyngeal squamous cel

206 zation of the skin from which multiple human papillomavirus (HPV)-positive squamous cell carcinomas (

207 Compared to primary human papillomavirus (HPV)-positive tumors, many recurrent and

208 The effective management of women with human papillomavirus (HPV)-positive, cytology-negative results

209 ienced an increase in the incidence of human papillomavirus (HPV)-related cancers that are not screen

210 his study was to determine the risk of human papillomavirus (HPV)-related carcinomas and premalignanc

211 As the demand for human papillomavirus (HPV)-related cervical screening increase

212 ients develop persistent, stigmatizing human papillomavirus (HPV)-related cutaneous and genital warts

213 The incidence of human papillomavirus (HPV)-related head and neck squamous cell

214 Cancer survivors are at high risk for human papillomavirus (HPV)-related morbidities; we estimated t

215 Patients with human papillomavirus (HPV)-related oropharyngeal cancer (OPC)

216 Importance: An escalating incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell

217 CC/UICC) staging system, developed for human papillomavirus (HPV)-unrelated disease, discriminates po

218 alignancy associated with infection by human papillomavirus (HPV).

219 and cancers related to infection with human papillomavirus (HPV).

220 persistent infection with a high-risk human papillomavirus (HPV).

221 ancer, a disease principally caused by human papillomavirus (HPV).

222 apillomas are common lesions caused by human papillomavirus (HPV).

223 E6AP by the E6 oncoprotein of distinct human papillomaviruses (HPV) contributes to the development of

224 Human papillomaviruses (HPV) replicate their genomes in differ

225 nsequence of persistent infection with human papillomaviruses (HPV).

226 with cytology (cytologic tests without human papillomavirus [HPV] tests).

227 tion (human cytomegalovirus [HCMV] and human papillomavirus [HPV]) and transcription (HSV-1, HCMV, an

228 ferences in infection-related (HIV and human papillomavirus [HPV]) cancers.

229 Infections with high-risk human papillomaviruses (HPVs) are a major cause of anogenital

230 Oncogenic human papillomaviruses (HPVs) are closely linked to major huma

231 At least 15 high-risk human papillomaviruses (HPVs) are linked to anogenital preneop

232 Human papillomaviruses (HPVs) are the etiological agents of ce

233 beta-Human papillomaviruses (HPVs) cause near ubiquitous latent ski

234 Infection by human papillomaviruses (HPVs) has been implicated in the aetio

235 The infectious process of human papillomaviruses (HPVs) has been studied considerably, a

236 High-risk human papillomaviruses (HPVs) infect epithelial cells and are

237 Human papillomaviruses (HPVs) infect the epidermis as well as

238 High-risk human papillomaviruses (HPVs) link their life cycle to epithel

239 pite preventive vaccines for oncogenic human papillomaviruses (HPVs), cervical intraepithelial neopla

240 Oncoviruses, including human papillomaviruses (HPVs), Epstein-Barr virus (EBV), and h

241 istent infection by specific oncogenic human papillomaviruses (HPVs), including HPV58, has been estab

242 any cancers, including those caused by human papillomaviruses (HPVs).

243 High-risk human papillomavirus (HR-HPV) causes nearly 100% of cervical c

244 The risk of incident high-risk human papillomavirus (HR-HPV) infection associated with recent

245 ina, to compare clearance of high-risk human papillomavirus (HR-HPV) infection between ethnicities.

246 e risk of anal cancer due to high-risk human papillomavirus (HR-HPV) is higher in women living with h

247 al squamous cell carcinomas, high-risk human papillomavirus (HRHPV) DNA is usually integrated into ho

248 Background: High-risk human papillomavirus (hrHPV) testing to triage women with mino

249 High-risk human papillomavirus (hrHPV) testing to triage women with mino

250 ated disease.IMPORTANCE High-risk-type human papillomaviruses (hrHPVs) cause 5% of all cancer cases w

251 Universal vaccination against the human papillomavirus, ideally with the nine-valent vaccine, al

252 Papillomaviruses infect and replicate in keratinocytes,

253 Human papillomaviruses infect mucosal and cutaneous epithelia,

254 oss clinical and histopathological images of papillomavirus infected lesions.

255 Human papillomavirus infection accounts for APOBEC3B upregulat

256 .9% (95% CI: 24.3-43.5%) for high-risk human papillomavirus infection from cervical samples and 78.6%

257 n cleavage of minor capsid protein L2 during papillomavirus infection has been difficult to directly

258 eled to recognize the signs of genital human papillomavirus infection.

259 In papillomavirus infections, the viral genome is establish

260 The dimeric 44-residue E5 protein of bovine papillomavirus is the smallest known naturally occurring

261 Here we show an interaction between papillomavirus L2 proteins and the related PX-FERM famil

262 n the discoveries made in the study of human papillomaviruses, Merkel cell carcinoma-associated polyo

263 ct tropism of HPV requires the use of animal papillomavirus models for therapeutic vaccine developmen

264 ore virome structure included herpesviruses, papillomaviruses, polyomaviruses, adenoviruses and anell

265 Analysis of MATH and outcome in human-papillomavirus-positive oropharyngeal squamous cell carc

266 Human papillomavirus prevalence and determinants of genotype-s

267 The papillomavirus (PV) E1 helicase contains a conserved C-t

268 The papillomavirus (PV) E2 protein is a DNA binding, protein

269 gh the Y102 residue of HPV E2.IMPORTANCE The papillomavirus (PV) is a double-stranded DNA tumor virus

270 nostic and therapeutic strategies.IMPORTANCE Papillomaviruses (PVs) are an ancient and heterogeneous

271 Papillomaviruses (PVs) are small, double-stranded DNA vi

272 ols on patient-derived xenografts from human papillomavirus-related (HPV(+)) head and neck squamous c

273 Human papillomavirus-related (HPV+) oropharyngeal cancer is a

274 also associated with increased risk of human papillomavirus-related cancers, including anal cancer (H

275 e of this approach to both prevent and treat papillomavirus-related disease.

276 Human papillomavirus replication is accomplished in concert wi

277 The beta genus of human papillomaviruses (ss-HPV) includes approximately 50 diff

278 ecular characteristics, including age, human papillomavirus status, tumor grade and TP53 mutation, an

279 Established models have suggested that human papillomaviruses target the retinoblastoma (RB1) and TP5

280 Human papillomavirus testing led to faster and more complete d

281 The trafficking of papillomaviruses to the host cell nucleus during their n

282 dentify cellular factors that regulate human papillomavirus type 16 (HPV16) gene expression, cervical

283 Although most cervical human papillomavirus type 16 (HPV16) infections become undetec

284 Several human papillomavirus type 16 (HPV16) oncoproteins contribute t

285 Oncogenic human papillomavirus type 16 (HPV16) or type 18 (HPV18) infect

286 Human papillomavirus type 16 DNA in oral rinses is common at d

287 mb-mediated epigenetic methylations in human papillomavirus type 16 E7 expressing cells, and increase

288 roteins from high-risk (HR-) oncogenic human papillomavirus type 58 (HPV58).

289 Human papillomavirus type 6 (HPV-6) and HPV-11 are the etiolog

290 17, is variable in strength depending on the papillomavirus type.

291 r gene transduction by three oncogenic human papillomavirus types, HPV16, HPV18, and HPV31.

292 demonstrated that the E2 proteins of diverse papillomavirus types, including bovine papillomavirus (B

293 In a survey of 20 additional HPV and animal papillomavirus types, we found that many, but not all, P

294 Human papillomavirus vaccination may represent an efficacious,

295 Human papillomavirus vaccination, stratified by the number of

296 , and reduced acellular pertussis; and human papillomavirus vaccines) in addition to time posttranspl

297 fter internalization, the nonenveloped human papillomavirus virion uncoats in the endosome, whereupon

298 cent clinical trial using the 9-valent human papillomavirus virus (HPV) vaccine has shown that antibo

299 Human papillomavirus virus type 16 (HPV-16) and HPV-18 cause a

300 ruses, human pegivirus 1, herpesviruses, and papillomaviruses were detected in RNA-seq data, but prop